Stockreport

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Preliminary IBTROZI net product revenue of approximately $15.7 million in the fourth quarter and $24.7 million since launch Preliminary unaudited cash, cash equivalen [Read more]